S&P Futures
3,366.50+13.75(+0.41%)Dow Futures
27,848.00+169.00(+0.61%)Nasdaq Futures
11,120.25+48.25(+0.44%)
ANI Pharmaceuticals, Inc. (ANIP)
Chart Events
Performance Outlook
| Previous Close | 30.37 |
| Open | 30.47 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 900 |
| Day's Range | 30.47 - 33.38 |
| 52 Week Range | 25.23 - 80.87 |
| Volume | 107,447 |
| Avg. Volume | 134,367 |
| Market Cap | 407.647M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.70 |
| Earnings Date | Aug 06, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.33 |
Fair Value
Related Research
- Zacks
ANI Pharmaceuticals (ANIP) Q2 Earnings Miss Estimates
ANI (ANIP) delivered earnings and revenue surprises of -2.82% and 6.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
ANI Pharmaceuticals Reports Second Quarter 2020 Results
ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2020.
- Business Wire
ANI Pharmaceuticals Appoints Experienced Pharmaceutical Executives, Jeanne Thoma and Antonio "Tony" Pera to Board of Directors
ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq:ANIP) today announced the appointments of Jeanne Thoma, President and Chief Executive Officer of SPI Pharma, Inc. and Antonio ("Tony") Pera, former President of Par Pharmaceutical to the ANI Pharmaceuticals Board of Directors. These appointments are effective immediately and increase ANI’s Board of Directors to seven members, including Nikhil Lalwani, who will join the Board next month when he starts as President and CEO of the Company on September 8, 2020.
